RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Roivant Sciences Stock

Roivant Sciences P/S 2025

Roivant Sciences P/S

67.12

Ticker

ROIV

ISIN

BMG762791017

WKN

A3C4MS

As of Jan 4, 2025, Roivant Sciences's P/S ratio stood at 67.12, a -7.19% change from the 72.32 P/S ratio recorded in the previous year.

The Roivant Sciences P/S history

Roivant Sciences Aktienanalyse

What does Roivant Sciences do?

Roivant Sciences Ltd is a biopharmaceutical company based in Basel, Switzerland. It was founded in 2014 by Vivek Ramaswamy, a former hedge fund manager. The company's idea was to develop "orphan molecules," which are drug compounds that have not been further developed by large pharmaceutical companies for various reasons. Roivant Sciences' business model is based on identifying therapy areas with high unmet medical needs. It then collaborates with academic institutions and other partners to search for orphan molecules that could be potentially interesting for these therapy areas. The molecules are further developed in the company's internal research and development laboratories. Roivant Sciences has established seven different subsidiary companies through its innovative approach to drug development and acquisition of other companies. Some of the most well-known subsidiaries include Axovant Sciences, Dermavant Sciences, Enzyvant Therapeutics, and Myovant Sciences. Each subsidiary of Roivant Sciences focuses on specific therapy areas. For example, Axovant Sciences focuses on developing therapies for neurological diseases such as Parkinson's and Alzheimer's, while Dermavant Sciences focuses on dermatology and Enzyvant Therapeutics concentrates on rare genetic diseases. Roivant Sciences has also raised a considerable amount of capital to finance its various companies. In 2017, the company raised $1.1 billion, expanding its presence in the global healthcare market. Products developed by Roivant Sciences' subsidiaries include Axovant's Nelotanserin, a potential medication for hallucinations and nightmares in Parkinson's patients, as well as Myovant's Leuprolide, a medication for treating prostate cancer. The company also has a partnership with Dartmouth College to advance research and development in neuroscience. The partnership aims to identify "specific molecular targets" for developing treatments for neurodegenerative diseases. In summary, Roivant Sciences Ltd is an innovative biopharmaceutical company that develops orphan molecules and specializes in various therapy areas. Its subsidiaries develop products for a range of diseases, from Alzheimer's to prostate cancer and rare genetic disorders. The company has raised a significant amount of capital to finance its operations and collaborates with academic institutions to advance its research and development. Roivant Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Roivant Sciences's P/S Ratio

Roivant Sciences's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Roivant Sciences's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Roivant Sciences's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Roivant Sciences’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Roivant Sciences stock

What is the price-to-earnings ratio of Roivant Sciences?

The price-earnings ratio of Roivant Sciences is currently 67.12.

How has the price-earnings ratio of Roivant Sciences changed compared to last year?

The price-to-earnings ratio of Roivant Sciences has increased by -7.19% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Roivant Sciences high compared to other companies?

Yes, the price-to-earnings ratio of Roivant Sciences is high compared to other companies.

How does an increase in the price-earnings ratio of Roivant Sciences affect the company?

An increase in the price-earnings ratio of Roivant Sciences would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Roivant Sciences affect the company?

A decrease in the price-earnings ratio of Roivant Sciences would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Roivant Sciences?

Some factors that influence the price-earnings ratio of Roivant Sciences are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Roivant Sciences pay?

Over the past 12 months, Roivant Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Roivant Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Roivant Sciences?

The current dividend yield of Roivant Sciences is .

When does Roivant Sciences pay dividends?

Roivant Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Roivant Sciences?

Roivant Sciences paid dividends every year for the past 0 years.

What is the dividend of Roivant Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Roivant Sciences located?

Roivant Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Roivant Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Roivant Sciences from 1/4/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/4/2025.

When did Roivant Sciences pay the last dividend?

The last dividend was paid out on 1/4/2025.

What was the dividend of Roivant Sciences in the year 2024?

In the year 2024, Roivant Sciences distributed 0 USD as dividends.

In which currency does Roivant Sciences pay out the dividend?

The dividends of Roivant Sciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Roivant Sciences

Our stock analysis for Roivant Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Roivant Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.